Accufix Surgical

Accufix Surgical is a private, commercial-stage medical device company founded in 2015 and headquartered in San Diego, California. The company has developed and received FDA approval for the Accu-Joint® implant, a novel solution for big toe (MTP joint) arthritis that emphasizes bone preservation and resurfacing rather than bone resection and fusion. This approach aims to provide patients with reduced pain, faster recovery, maintained joint mobility, and preserved future surgical options. The company is now focused on commercializing this product to surgeons and patients as an alternative to the standard-of-care fusion procedure.

A joint resurfacing implant system based on principles of bone preservation and anatomical load transfer. It uses patented instrumentation for minimal bone resection (1mm) and a non-weight-bearing implant design that replaces cartilage rather than the entire joint.

Competition is primarily the standard of care: joint fusion (arthrodesis) with plates and screws. Other competitors include historical toe joint implants (e.g., silicone, two-component total joints) which often require bone resection and have mixed long-term results. The Accu-Joint's main differentiator is its bone-preserving, resurfacing approach, positioning it as a third way between fusion and traditional replacement.